Stock Analiz

Intercure Ltd. INCR

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$3.79Market cap $57M
Open the interactive analysis →

Intercure Ltd. (INCR) is a healthcare company listed in the US with a market value of about $57M. In fiscal year 2024 it had revenue of $65M and net income of -$19M, a net margin of -28.4%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 91% a year, a 5-year average ROIC of -3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 41% below the current price.

About Intercure

Intercure is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $3M in 2019 to $65M in 2024, growth of about 90.9% a year. It was profitable in 2 of the last 6 years in our data.

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.9
P/B0.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-34.4%
Shareholder yield0.0%
Intrinsic value vs. price−41%

Growth and quality

Revenue growth (1 yr)-33.3%
Revenue growth (5 yrs, per year)90.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-17.9%
ROIC (5-yr avg.)-3.4%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 6 years

Fiscal year202420232022202120202019
Revenue$65M$98M$110M$71M$20M$3M
Net income-$19M-$17M$13M$2M-$12M-$2M
Free cash flow-$20M-$16M$9M$5M-$4M-$11M
EPS (diluted)$-1.24$-1.14$0.85$0.10$-0.77$-0.11
Net margin-28.4%-17.4%11.5%2.1%-57.2%-66.0%
ROIC-9.7%-5.2%6.9%4.2%-13.1%-1.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Intercure stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 41% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Intercure pay a dividend?

Not currently.

Is Intercure a good stock to buy?

We do not give buy or sell advice. Intercure scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.